Impact of vessel maturation on antiangiogenic therapy in ovarian cancer
- 1 April 2008
- journal article
- conference paper
- Published by Elsevier BV in American Journal of Obstetrics and Gynecology
- Vol. 198 (4), 477.e1-477.e10
- https://doi.org/10.1016/j.ajog.2007.12.028
Abstract
No abstract availableKeywords
This publication has 39 references indexed in Scilit:
- Phase II Trial of Bevacizumab in Persistent or Recurrent Epithelial Ovarian Cancer or Primary Peritoneal Cancer: A Gynecologic Oncology Group StudyJournal of Clinical Oncology, 2007
- Dual Targeting of Endothelial Cells and Pericytes in Antivascular Therapy for Ovarian CarcinomaClinical Cancer Research, 2007
- Vascular endothelial growth factor (VEGF) pathway as a therapeutic target in gynecologic malignanciesGynecologic Oncology, 2007
- Preoperative serum vascular endothelial growth factor as a prognostic parameter in ovarian cancerGynecologic Oncology, 2006
- Intraperitoneal Chemotherapy of Ovarian Cancer: A Review, With a Focus on Practical Aspects of TreatmentJournal of Clinical Oncology, 2006
- Stress Hormone–Mediated Invasion of Ovarian Cancer CellsClinical Cancer Research, 2006
- Antivascular Therapy for Orthotopic Human Ovarian Carcinoma through Blockade of the Vascular Endothelial Growth Factor and Epidermal Growth Factor ReceptorsClinical Cancer Research, 2005
- Endothelial PDGF-B retention is required for proper investment of pericytes in the microvessel wallGenes & Development, 2003
- The biology of VEGF and its receptorsNature Medicine, 2003
- Induction of VEGF in perivascular cells defines a potential paracrine mechanism for endothelial cell survivalThe FASEB Journal, 2001